http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020522565-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2018-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2020522565-A |
| titleOfInvention | Polysubstituted pyrimidines inhibiting the production of prostaglandin E2, process for their production and their use |
| abstract | The present invention describes pyrimidine-based compounds of general formula (I). The compounds described reduce the production of prostaglandin E 2 . At concentrations that reduce the production of this factor by 50%, these compounds have no negative effect on cell viability and show no cytotoxicity. Furthermore, the present invention provides a process for the preparation of compounds of general formula I. The invention also provides pharmaceutical compositions comprising the polysubstituted pyrimidines according to the invention and the use of these compounds for the treatment of inflammatory diseases. |
| priorityDate | 2017-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 300.